MBX BIOSCIENCES INCMBX
ASignal's systematic analysis rates MBX as Neutral.
Reflects the latest available analysis · analyzed Oct 20, 2026
The case on MBX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.01x)
- High cash position ($418.58M cash vs $3.34M debt)
- High liquidity (current ratio 18.08x)
- Negative operating cash flow ($-82.67M)
- Negative free cash flow ($-53.01M)
- Negative return on equity (-33.17%)
- Negative forward P/E (-13.38x) and EV/EBITDA (-17.95x)
- Zero gross, operating, and net margins
- Limited news coverage (only 1 source)
See the full verdict on MBX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MBX
Most investors never get a second opinion, let alone several. ASignal runs MBX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.